In-depth case study webinar: how MolMed achieved large-scale GMP production of LV and RV Vectors
Sponsor
Case study: MolMed presents process development and large-scale GMP production for lentiviral (LV) and retroviral (RV) vectors in the iCELLis® 500 fixed-bed bioreactor
MolMed is a biotechnology company focused on research, development and manufacturing of innovative therapies to treat cancer and rare genetic diseases. MolMed has developed a robust and scalable process for the industrial scale production of both LV and RV vectors for use in gene-modified cell therapy using the iCELLis bioreactor platforms.
Molmed present the development and optimization of their LV and RV vector production processes in the scale down iCELLis nano bioreactor. The processes were then scaled up to the production scale iCELLis 500 bioreactor and results were comparable to processes performed at small scale.
Webinar participants learn:
- How an iCELLis bioreactor can used for commercial scale vector production
- MolMed’s process development and large-scale production process using the iCELLis platform
- How to develop industrial scale viral vector production
You might also like
Large-scale LVV production: from industry-leading process development to high quality GMP vector
Supporting development of mRNA-based therapies by addressing large scale purification challenges
Breaking barriers in viral vector titer analysis speed, volume, and data quality
Case study: Optimization of lentiviral vector production from early stages to GMP
